PF 4965842

Drug Profile

PF 4965842

Alternative Names: PF 04965842; PF4965842

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Discontinued Lupus vulgaris; Plaque psoriasis

Most Recent Events

  • 04 Apr 2017 Pfizer completes a phase II trial in Atopic dermatitis in Australia, Canada, Germany, Hungary, USA (PO) (NCT02780167)
  • 15 Apr 2016 Phase-II clinical trials in Atopic dermatitis in Australia, Canada, Germany, Hungary, USA (PO) (NCT02780167)
  • 28 Oct 2015 Discontinued - Phase-I for Lupus (In volunteers) in Belgium and USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top